Mosaic ImmunoEngineering Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2019
Net Income	-0.69	-0.92	-1.01	-2.38	-3.68	Upgrade
Loss (Gain) From Sale of Investments	-	-	-0.43	-0.34	-	Upgrade
Stock-Based Compensation	-	0	0.02	0.3	1.31	Upgrade
Other Operating Activities	0.07	0.11	0.04	0.09	0.18	Upgrade
Change in Accounts Payable	-0	-0.02	-0.01	0.02	0.03	Upgrade
Change in Income Taxes	-	-	-	-	0.03	Upgrade
Change in Other Net Operating Assets	0.51	0.58	0.89	1.62	1.46	Upgrade
Operating Cash Flow	-0.11	-0.24	-0.5	-0.69	-0.68	Upgrade
Investment in Securities	-	-	0.43	0.34	0.03	Upgrade
Investing Cash Flow	-	-	0.43	0.34	0.03	Upgrade
Short-Term Debt Issued	-	0.27	-	-	-	Upgrade
Long-Term Debt Issued	-	-	-	0.34	0.53	Upgrade
Total Debt Issued	-	0.27	-	0.34	0.53	Upgrade
Short-Term Debt Repaid	-	-0.07	-	-	-	Upgrade
Total Debt Repaid	-	-0.07	-	-	-	Upgrade
Net Debt Issued (Repaid)	-	0.2	-	0.34	0.53	Upgrade
Financing Cash Flow	-	0.2	-	0.34	0.53	Upgrade
Net Cash Flow	-0.11	-0.04	-0.06	-0.01	-0.13	Upgrade
Cash Interest Paid	-	0.01	-	-	-	Upgrade
Cash Income Tax Paid	0	0	0	0	0	Upgrade
Levered Free Cash Flow	0.07	0.01	-0.07	0.2	0.59	Upgrade
Unlevered Free Cash Flow	0.12	0.06	-0.02	0.24	0.61	Upgrade
Change in Working Capital	0.5	0.57	0.88	1.64	1.52	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.